- Types of Eczema
- Eczema in Children
- Living Well
- Eczema Products
- Get Involved
- For Medical Professionals
The Swiss scientists theorized that the same immune cells that protect us against the normally harmless Malassezia fungus might also play a fundamental role in triggering atopic dermatitis.
Galderma’s nemolizumab and Dermira’s lebrikizumab are two new biologics for atopic dermatitis that are working their way toward FDA approval.
A NEA-funded study found that mothers of children with moderate to severe atopic dermatitis are more likely to experience sleep loss and caregiver fatigue.
The researchers suggest doctors combine basic skincare techniques with cutting-edge treatments to maximize the well-being of their patients.
Historically, pediatric atopic dermatitis patients have been excluded from the early stages of the drug development process, but this soon may change.
A large-scale study conducted in the United Kingdom concluded that people with severe atopic dermatitis may be at an increased risk for cardiovascular disease.
Research studies reveal that people with atopic dermatitis are more likely to harbor suicidal thoughts than those without the disease.
In the “Golden Age of Eczema,” people with atopic dermatitis have more treatment options than ever before, with even more drugs making their way to pharmacy shelves.
Research reveals children with atopic dermatitis under age 2 are at greater risk for asthma and allergies.
New evidence shows that Lactobacillus-containing probiotic strains may reduce disease severity in children age 3 and under.